Mapping Pathways is a multi-national project to develop and nurture a research-driven, community-led global understanding of the emerging evidence base around the adoption of antiretroviral-based prevention strategies to end the HIV/AIDS epidemic. The evidence base is more than results from clinical trials - it must include stakeholder and community perspectives as well.

11 June 2012

FDA Delays Approval for HIV Prevention Drug

via Washingtonpost.com, by Brian Vastag

The Food and Drug Administration is delaying by three months a decision on whether to approve a drug for preventing infection with HIV, the virus that causes AIDS.

An agency decision on the drug Truvada, made by Gilead Sciences, was expected by June 15. But the decision was pushed back to give the agency time to review a new Gilead plan to limit the risks to healthy people taking the drug, Cara Miller, a company spokeswoman, said Friday.

If approved, Truvada would become the first drug marketed for prevention of HIV. The FDA will now make a decision by Sept. 14.

In May, a committee of FDA advisers recommended that the agency approve Truvada for HIV prevention in specific high-risk groups, including men who have sex with men and partners of those infected with HIV.

After that meeting, the FDA asked Gilead to revise its risk-management plan for the drug, Miller said.

She declined to provide details on how Gilead revised this plan, which is known as a risk evaluation and management strategy.

During the May meeting, FDA advisers wrestled with safety concerns, including fears that men taking the drug would see it as an excuse to stop using condoms, and worries that healthy people would not take the drug daily as prescribed.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

Mapping Pathways @ TasP and PrEP summit in London

Original content from the Mapping Pathways blog team

While last year was all about data collection for the Mapping Pathways project, this year our core mission is to disseminate findings and liaise with the global HIV-treatment and prevention community at large around the use of ARVs for prevention.

Mapping Pathways members will have the chance to do just that in London this week.  The International Association of Physicians in AIDS Care (IAPAC), in partnership with the British HIV Association (BHIVA), is currently hosting an evidence summit (June 11 and 12) titled “Controlling the HIV Pandemic with Antiretrovirals: Treatment as Prevention and Pre-exposure Prophylaxis."

Jim Pickett from the AIDS Foundation of Chicago, will be representing Mapping Pathways and presenting some PrEP-specific findings at the summit. Ben Brown, another member of the Mapping Pathways team from the Desmond Tutu HIV Foundation, is also on a panel, and RAND team members Molly Morgan Jones and Joanna Chataway will be attending.

“The summit brings together a whole mix of people – from community advocacy organizations, drug companies, insurance companies, researchers, policymakers and advocates from 50 countries – both global north and global south. All actors that have a stake in HIV-prevention and treatment will be there. There will be a goldmine of information and a good opportunity to talk about the Mapping Pathways project and what we’re trying to accomplish,” says Pickett.

The summit will serve as a forum for the presentation of data and discussion about the implementation of Treatment as Prevention (TasP – which Mapping Pathways refers to as TLC+) and PrEP in different settings.

An important deliverable of the summit is a consensus statement outlining some key TasP and PrEP implementation recommendations which would then be disseminated at the International AIDS Conference in Washington, DC this summer and to IAPAC’s clinician network in over 100 countries as well as with their other medical and nursing tie-ups worldwide.

We will share Jim’s slides on the blog, and provide a link to all the presentations made at the summit as well in the coming days.

Stay tuned to the Mapping Pathways blog for news and updates from the IAPAC summit and the upcoming AIDS 2012 conference in July in Washington D.C.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

08 June 2012

Improving the Production of Tenofovir

via AllAfrica.com, by Khopotso Bodibe


The national health department has contracted additional pharmaceutical manufacturers to make up the critical shortage of the antiretroviral tenofovir across the country.

HIV clinicians and doctors warned last week that the continued stock out of tenofovir and the failure to advise health workers on how to deal with it was a looming disaster.

Reports of stock outs go as far back as October last year with the explanation given that the drug suppliers Aspen Pharmacare and Sonke Pharmaceuticals were not able to meet the demand once they were awarded the tender.

It emerged this week that the national health department had directed provinces to order tenofovir from two additional suppliers.

Dr Anban Pillay, Cluster Manager for Financial Planning and Health Economics in the national health department, confirmed that Adcock Ingram Pharmaceuticals as well as Cipla Medpro Pharmaceuticals were now also supplying tenofovir to provinces.

"The procurement rules allow that. Obviously, there's a good reason for it. The current suppliers are not able to keep up with the total need. So, for the balance they are allowed to go out and get it from other suppliers," Pillay explained.

Aspen Pharmacare and Sonke Pharmaceuticals were initially contracted to supply tenofovir to the public sector antiretroviral programme, but they have struggled to meet the demand.

"The split between Aspen Pharmacare and Sonke is a 70 30 split, meaning that 70% of the volume goes to Aspen and 30% to Sonke. Unfortunately, Sonke hasn't been able to ramp up its production to the level that is required to meet the demand," said Pillay.

The national health department estimates that tenofovir is dispensed to about 1.2 million patients every month.

Aspen Pharmacare was only able to increase its production to the 70 per cent tender requirement in recent weeks. With Sonke Pharmaceuticals not being able to supply its quota of the tender, the supplies from Aspen Pharmacare were not sufficient to serve all patients on tenofovir, resulting in the shortage.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

Tanzania Considers Compulsory HIV Testing for All Citizens

via AllAfrica.com, by Alvar Mwakyusa

People living with HIV/AIDS (PLHAs) and a section of lawmakers have proposed that every person living in the country be subjected to compulsory HIV testing in a bid to promote the fight against the disease.

However, not everyone supports the idea. Some of the people interviewed by the 'Daily News' are against the idea. Many point out that it is against human rights to compel someone to undergo a HIV test or any other medical tests.

Speaking in Dar es Salaam recently, the board chairperson of the National Council of People Living with HIV/AIDS (NACOPHA), Mr Vitalis Makayula, was of a view that if the fight against the disease was to be won, then all people must be aware of their HIV status.

He also said that those found to be positive must disclose their status. Mr Makayula made these remarks at a seminar organized by the Association of Journalists Against AIDS in Tanzania (AJAAT), to sensitize journalists on the HIV and AIDS Prevention and Control Act (HAPCA) of 2008.

"Tackling HIV/AIDS would be more effective if everyone tested for HIV and disclose his/her status. Otherwise it is like fighting an enemy you don't know," he stressed.

Mr Makayula was also optimistic that if everyone knew their HIV status stigma against those found to be positive would be reduced.When contacted for comment, the Deputy Minister for Health and Social Welfare, Dr Seif Suleiman Rashid, said that there are factors that must be considered before deciding if testing should be compulsory or not.

"Before deciding on the matter we should consider revising the current legislation, human rights and availability of resources, among others. It is an issue which requires discussion among experts and stakeholders," he explained in a telephone interview.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

07 June 2012

FDA Moves Deadline for Approval of Truvada as PrEP to September


The following is an official communication from Gilead re: Truvada as PrEP.

The U.S. Food and Drug Administration (FDA) has advised Gilead that it has extended the target date for its priority review of Truvada for reducing the risk of HIV acquisition (also known as PrEP) by three months. This means that the agency will now make a decision on whether to approve Truvada for PrEP by September 14, 2012. The FDA has indicated that this extension relates to the agency’s standard administrative procedures for reviewing Gilead’s proposed Risk Evaluation and Mitigation Strategy (REMS) for Truvada as PrEP.  As was discussed at the FDA Advisory Committee Meeting last month, there are many components of a REMS, including a Medication Guide, educational training and an implementation system, all of which may require additional time for adequate FDA review. Gilead will continue to work closely and collaboratively with the FDA during this process, and [we] will keep you advised of any additional updates along the way. 

Click here for a previous post on Truvada and the FDA for more info, including links to a webcast of the FDA meeting and presentation materials.

[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]